AUPH
Closed
Aurinia Pharmaceuticals Inc
7.48
-0.99 (-11.69%)
Last Update: 01 Jul 2025 23:19:00
Yesterday: 8.47
Day's Range: 7.45 - 8.48
Send
sign up or login to leave a comment!
When Written:
10.96
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies to treat autoimmune diseases. The company is headquartered in Victoria, British Columbia, Canada, and has a subsidiary in Rockville, Maryland, USA.
Aurinia's lead product is voclosporin, a drug candidate for the treatment of lupus nephritis, a potentially life-threatening autoimmune disease that affects the kidneys. The drug has completed Phase 3 clinical trials and is currently under review by regulatory authorities in the US, Europe, and Canada.
In addition to lupus nephritis, Aurinia is also developing voclosporin for the treatment of other autoimmune diseases, including focal segmental glomerulosclerosis (FSGS) and dry eye syndrome.
The company was founded in 1993 and went public in 2013. As of 2021, Aurinia Pharmaceuticals has a market capitalization of over $3 billion and employs over 200 people.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Aurinia's lead product is voclosporin, a drug candidate for the treatment of lupus nephritis, a potentially life-threatening autoimmune disease that affects the kidneys. The drug has completed Phase 3 clinical trials and is currently under review by regulatory authorities in the US, Europe, and Canada.
In addition to lupus nephritis, Aurinia is also developing voclosporin for the treatment of other autoimmune diseases, including focal segmental glomerulosclerosis (FSGS) and dry eye syndrome.
The company was founded in 1993 and went public in 2013. As of 2021, Aurinia Pharmaceuticals has a market capitalization of over $3 billion and employs over 200 people.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








